CIMS Bahawalpur
Bahawalpur, Punjab Province, 63100, Pakistan
NCT Number: NCT07307092
Preterm labour is a major cause of neonatal morbidity and mortality worldwide. Progesterone supplementation is known to help reduce the risk of preterm birth in high-risk women. This randomized controlled trial compared the effectiveness of intramuscular progesterone and rectal progesterone in preventing preterm labour among pregnant women who had undergone cervical cerclage. The study aimed to determine which route of progesterone administration provides better pregnancy prolongation and improved neonatal outcomes.
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Not applicable
Bahawalpur, Punjab Province, 63100, Pakistan
Background:
Preterm labour remains one of the leading causes of perinatal mortality and long-term neonatal complications. Cervical insufficiency, often managed by cervical cerclage, is a recognized risk factor for preterm birth. Progesterone supplementation helps maintain uterine quiescence and cervical integrity, but the optimal route of administration after cerclage is not well established.
Objective:
To compare the efficacy of intramuscular progesterone versus rectal progesterone in preventing preterm labour among women who underwent cervical cerclage.
Methods:
This single-centre, randomized controlled trial was conducted in the Department of Obstetrics & Gynecology, Bahawal Victoria Hospital, Bahawalpur, Pakistan. Eligible women with singleton pregnancies who had undergone cervical cerclage were randomly assigned to receive either weekly intramuscular progesterone (250 mg) or daily rectal progesterone suppositories (400 mg) from 16 to 36 weeks of gestation. The primary outcome was the incidence of preterm labour before 37 weeks. Secondary outcomes included gestational age at delivery, neonatal birth weight, NICU admission, and maternal side effects.
Significance:
This study provides evidence on the comparative effectiveness of two commonly used routes of progesterone administration in women with cerclage, aiming to identify the safer and more convenient regimen for prolonging pregnancy and improving neonatal outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Pregnant women aged 18-45 years
Singleton pregnancy
Gestational age between 16 and 24 weeks at enrollment
Diagnosed with cervical insufficiency and scheduled for or recently undergone cervical cerclage
Willing to receive progesterone therapy and provide written informed consent
Exclusion criteria
Multiple pregnancy
Known fetal anomalies
Severe maternal comorbidities (e.g., hypertension, diabetes, cardiac disease)
History of allergy or hypersensitivity to progesterone or related compounds
Contraindications to progesterone use
Women who declined to participate or were non-compliant with follow-upInclusion Criteria:
-
Exclusion criteria
-
Hydroxyprogesterone caproate 250 mg administered intramuscularly once weekly from 16 to 36 weeks of gestation following cervical cerclage. Used to maintain uterine quiescence and prevent preterm labour.
Micronized progesterone 400 mg suppository administered rectally once daily from 16 to 36 weeks of gestation following cervical cerclage. Intended to provide sustained progesterone support and prevent preterm labour.
Time frame: 16-36 weeks until delivery
Time frame: At delivery
Time frame: At birth
Time frame: Immediately post-delivery
Time frame: Within 24 hours of birth
Time frame: During treatment period (16-36 weeks)
Hina Mukhtar
Other
Comparison of Intramuscular Progesterone and Rectal Progesterone in the Prevention of Preterm Labour in Patients Undergoing Cervical Cerclage: A Randomized Controlled Trial
Acronym: PROCER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01340222
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Dijon, France
View Trial DetailsNCT02092688
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Bern, Switzerland
View Trial DetailsNCT02284867
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
View Trial DetailsNCT01429545
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Al Ain City, Abudhabi, United Arab Emirates
View Trial Details